Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï¿¡¼­ Apoptosis¿Í bcl-2 ¹× p53´Ü¹é ¹ßÇö¿¡ °üÇÑ ¿¬±¸ A Study of Apoptosis, and bel-2 and p53 Expressions in Breast Cancer

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 3È£ p.412 ~ 421
±èµ¿¿ø, À̽ÅÁ¦, °í±¤±Õ,
¼Ò¼Ó »ó¼¼Á¤º¸
±èµ¿¿ø (  ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ¼Óº´¿ø

À̽ÅÁ¦ (  ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ¼Óº´¿ø
°í±¤±Õ (  ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ¼Óº´¿ø

Abstract

¼­·Ð
¹ß¾Ï°úÁ¤¿¡¼­´Â ¼¼Æ÷ÀÇ ºñÁ¤»óÀûÀÎ Áõ½Ä »Ó ¾Æ´Ï¶ó °èȹµÇ¾îÁø ¼¼Æ÷»ç, Áï ¾ÆÆ÷Åä¿ì½Ã½º
(apoptosis)°¡ °ü¿©ÇÏ°Ô µÇ¸ç, ¾ÆÆ÷Åä¿ì½Ã½ºÀÇ ¾ïÁ¦¿Í À¯µµ¿¡ °ü¿©ÇÏ´Â À¯ÀüÀÚ·Î bcl-2¿Í
p53À¯ÀüÀÚ°¡ ÀÖ´Ù.
bcl-2 À¯ÀüÀÚ´Â ¾ÆÆ÷Åä¿ì½Ã½º¸¦ ¾ïÁ¦ÇÏ¿© ¼¼Æ÷ ¼ö¸íÀ» ¿¬Àå½ÃÄÑ ¼¼Æ÷ÀÇ »ýÁ¸±â°£ Áß ´Ù¸¥
¾ÏÀ¯ÀüÀÚÀÇ Çª°¡ÀûÀÎ ¿µÇâÀ» ¹ÞÀ» ¼ö ÀÖ´Â ±âȸ¸¦ Áõ°¡½ÃÅ´À¸·Î½á ¾ÏÀ» À¯¹ßÇÏ´Â °ÍÀ¸·Î ¾Ë
·ÁÁ® ÀÖÀ¸³ª, bcl-2 À¯ÀüÀÚ°¡ ¾ÆÆ÷Åä¿ì½Ã½º¸¦ ¾ïÁ¦ÇÏ´Â Á¤È®ÇÑ ±âÀüÀº ¾ÆÁ÷ È®¸³µÇ¾î ÀÖÁö
¾ÊÀ¸¸ç, ¾Æ¸¶µµ À¯ÀüÀÚ°¡ Ç×»êÈ­Á¦, ´Ü¹éÁúºÐÇØÈ¿¼Ò ¾ïÁ¦Á¦, ¶Ç´Â ¼¼Æ÷°¡ ¾ÆÆ÷Åõ¿ì½Ã½º °úÁ¤
¿¡ µµ´ÞÇÏÁö ¸øÇϵµ·Ï ÇÏ´Â ÀÏÁ¾ÀÇ ¹æ¾î º® ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ÃßÃøÇÏ°í ÀÖ´Ù. bel-2À¯Àü
ÀÚ¿¡ ´ëÇÑ ÃʱâÀÇ ¿¬±¸´Â ÁÖ·Î B ¸²ÇÁ±¸ ±â¿øÀÇ ¿©Æ÷Çü ¸²ÇÁÁ¾¿¡¼­ ÀÌ·ç¾îÁ³´Âµ¥ 14¹ø°ú
18¹ø ¿°»öüÀÇ »óÈ£ ÀüÁ°¡ ÀϾ°í ÀÌ·Î ÀÎÇØ bel-2 mRNA¿Í ´Ü¹éÀÌ °ú»ý»êµÊÀ¸·Î¼­
bel-2´Ü¹éÀÌ ¹ßÇöµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ³Áö¸¸, ÇöÀç´Â À¯¹æÀ» ºñ·ÔÇÑ ¿©·¯ »óÇǼ¼Æ÷ ±â¿øÀÇ ¾Ï
Á¾°ú ½Å°æ°è Á¾¾ç¿¡¼­ ¿°»öüÀÇ »óÈ£ÀüÁ ¾øÀ̵µ bcl-2´Ü¹éÀÌ ¹ßÇöµÈ´Ù´Â °ÍÀÌ ¹àÇôÁ³´Ù.
p53 À¯ÀüÀÚ´Â 17¹ø ¿°»öüÀÇ ´Ü¿Ï¿¡ À§Ä¡ÇÏ´Â Á¾¾ç¾ïÁ¦ À¯ÀüÀڷμ­ Á¤»óÀûÀ¸·Î´Â ¾ÆÆ÷Åä
¿ì½Ã½º¸¦ À¯µµÇϳª µ¹¿¬º¯ÀÌ°¡ ÀϾ¸é ¹Ý´ë·Î ¾ÆÆ÷Åä¿ì½Ã½º¸¦ ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ
À¸¸ç, ÀÌ¿Í °°Àº µ¹¿¬º¯ÀÌÇü p53À¯ÀüÀÚ¿¡ ÀÇÇÑ ¾ÆÆ÷Åä¿ì½Ã½ºÀÇ ¾ïÁ¦´Â ¾ÏÁ¾ÀÇ È­Çпä¹ýÁ¦
¶Ç´Â ¹æ»ç¼±Ä¡·á¿¡ ´ëÇÑ ³»¼º°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù. ¾ÆÆ÷Åä¿ì½Ã½º¿¡
¼­ÀÇ bcl-2¿Í P53À¯ÀüÀÚ »óÈ£°£ÀÇ °ü·Ã¼º¿¡ ´ëÇؼ­´Â ¾ß»ýÇü p53¿¡ ÀÇÇØ À¯¹ßµÈ ¾ÆÆ÷Åä¿ì
½Ã½º¸¦ bel-2°¡ ¾ïÁ¦ÇÑ´Ù´Â º¸°í¿Í µ¹¿¬º¯ÀÌÇü p53 À¯ÀüÀڻ깰ÀÌ bel-2À¯ÀüÀÚ¸¦ ÇÏÇâÁ¶Àý
ÇÑ´Ù´Â º¸°í°¡ ÀÖÀ¸³ª ¸íÈ®ÇÏ°Ô ±Ô¸íµÇ¾î ÀÖÁö´Â ¾Ê´Ù.
À¯¹æ¾Ï¿¡¼­ bcl-2 ¹× p53À¯ÀüÀÚ¿Í ¿¹ÈÄ¿ÍÀÇ »ó°ü°ü°è¿¡ ´ëÇؼ­´Â bel-2´Ü¹éÀÌ °ú¹ßÇö µÉ
¼ö·Ï ¿¹ÈÄ°¡ ¾çÈ£ÇÏ°í p53 À¯ÀüÀڻ깰ÀÌ °ú¹ßÇö µÉ¼ö·Ï ¿¹ÈÄ°¡ ³ª»Û °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸³ª
(15¡­17) µ¶¸³ÀûÀÎ ¿¹ÈÄ ÀÎÀڷμ­ÀÇ °¡Ä¡°¡ ¾ø´Ù´Â º¸°íµµÀÖ´Ù.
ÀÌ¿¡ ÀúÀÚµéÀº À¯¹æ¾Ï¿¡¼­ ¾ÆÆ÷Åä¿ì½Ã½ºÀÇ Á¤µµ¿Í ¾ÆÆ÷Åä¿ì½Ã½º¸¦ Á¶ÀýÇϴµ¥ À־ ¼­
·Î »ó¹ÝµÈ ÀÛ¿ëÀ» ÇÏ´Â À¯ÀüÀÚ·Î ¾Ë·ÁÁ® ÀÖ´Â bel-2¿Í p53ÀÇ ¹ßÇö Á¤µµ¸¦ ¾Ë¾Æº¸°í À̸¦ ±â
Á¸ÀÇ ¿¹ÈÄ ÀÎÀÚµé°ú ºñ±³ ºÐ¼®ÇÏ¿© ¾ÆÆ÷Åä¿ì½Ã½º¿Í µÎ À¯ÀüÀÚ »çÀÌÀÇ ¿¬°ü¼º°ú À̵éÀÌ ¿¹ÈÄ
ÃßÁ¤ÀÎÀڷμ­ÀÇ °¡Ä¡°¡ ÀÖ´ÂÁö¸¦ ¾Ë¾Æº¸±â À§ÇÏ¿© º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.

Purpose : This study was undertaken for evaluation of the extent of apoptosis and
expression of the bcl-2 gene and p53 gene as prognostic factors in breast cancer.
Materials and Methods : The extent of apoptosis was determined by the 3 end-labeling
method of DNA in tissue sections and the expressions of bcl-2 and p53 was determined
by immunohistochemical staining in 41 cases of breast carcinomas.
Result : bcl-2 was correlated with ER positivity (p=0.005), with nuclear grade
(p=0.001), and with tumor size (p=0.019), whereas it was inversely correlated with
apoptosis (p= 0.018). No association was found with axillary nodal status. Apoptosis was
not associated with clinicopathological parameters, such as ER positivity, nuclear grade,
tumor size, and lymph node status. p53 was not associated with above
clinicopathological parameters. No relationship between the expression of bcl-2 and p53
was found.
Conclusion : These results suggest that bcl-2 protein inhibit apoptosis, and its
expression is associated with favorable clinicopathological features.

Å°¿öµå

Breast carcinoma; Apoptosis; bcl-2; p53;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS